The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Lipodystrophy and WastingLipodystrophy and Wasting
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

FDA says they will consider new-fill for those who have started treatment
Dec 10, 2001

I received a call from the FDA on this issue, and the representative said that they would offer new-fill on a compassionate use basis to those who have already started treatment. They will require the following: 1) A narrative from the physician stating why new-fill is better for the patient than any other approved treatment (such as collagen) 2) IRB approval from a reviewer hired by the physician. Apparently this is easier to do than it sounds. 3) Informed consent from the patient. 4) Concurrence by a physician independent of the providing physician.

These will be reviewed on a case by case basis. I do not know the location to fax the info, but I will E-mail it to you as soon as I receive it.

The contact person at FDA is Mr. Paul Williams, at 301-594-1190, extension 110. He has been very helpful in this effort. Thank you for your efforts in this task as well.

Response from Dr. Fisher

I will post this for others to see. Thank you. AF

Why's of NewFill FDA BAN
Steriods fight waisting?

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint